# Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas

> **NCT01960569** · PHASE4 · UNKNOWN · sponsor: **MinaPharm Pharmaceuticals** · enrollment: 200 (estimated)

## Conditions studied

- r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas

## Interventions

- **DRUG:** active product ( Thrombexx) assigned to arm 1
- **OTHER:** Placebo assigned to arm 2

## Key facts

- **NCT ID:** NCT01960569
- **Lead sponsor:** MinaPharm Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2014-01
- **Final completion:** 2014-04
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2013-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960569

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960569, "Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01960569. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*